BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32421817)

  • 1. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
    Iñiguez-Ariza NM; Jasim S; Ryder MM; Chintakuntlawar AV; Morris JC; Hilger CR; Menefee ME; Smallridge RC; Karlin NJ; Alcaino C; Bible KC
    J Clin Endocrinol Metab; 2020 Jul; 105(7):e2346-57. PubMed ID: 32421817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of primary and metastatic thyroid cancers.
    Máximo V; Melo M; Zhu Y; Gazzo A; Sobrinho Simões M; Da Cruz Paula A; Soares P
    Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 38015791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
    Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
    J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of
    Murugan AK; Qasem E; Al-Hindi H; Alzahrani AS
    Mol Clin Oncol; 2021 Oct; 15(4):210. PubMed ID: 34462665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
    Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
    Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
    Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
    Tirrò E; Martorana F; Romano C; Vitale SR; Motta G; Di Gregorio S; Massimino M; Pennisi MS; Stella S; Puma A; Gianì F; Russo M; Manzella L; Vigneri P
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31540307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
    Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
    Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
    [No Abstract]   [Full Text] [Related]  

  • 14. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas.
    Jin M; Song DE; Ahn J; Song E; Lee YM; Sung TY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not the same thing: metastatic PTCs have a different background than ATCs.
    de Biase D; Torricelli F; Ragazzi M; Donati B; Kuhn E; Visani M; Acquaviva G; Pession A; Tallini G; Piana S; Ciarrocchi A
    Endocr Connect; 2018 Dec; 7(12):1370-1379. PubMed ID: 30400028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
    Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
    J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience.
    Moore A; Bar Y; Maurice-Dror C; Finkel I; Goldvaser H; Dudnik E; Goldstein DA; Gordon N; Billan S; Gutfeld O; Wolf I; Popovtzer A
    Medicine (Baltimore); 2021 Jun; 100(25):e26388. PubMed ID: 34160418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Bikas A; Ahmadi S; Pappa T; Marqusee E; Wong K; Nehs MA; Cho NL; Haase J; Doherty GM; Sehgal K; Barletta JA; Alexander EK; Landa I
    Clin Cancer Res; 2023 Jul; 29(14):2678-2685. PubMed ID: 37260297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.